Group 1 - The core point of the news is that 精优药业 (Jingyou Pharmaceutical) experienced a significant stock price increase of 13.56%, reaching HKD 0.134, with a trading volume of HKD 2.323 million [1] - The company has entered into three subscription agreements on August 14, 2025, with different investors, agreeing to issue a total of 136 million shares at a subscription price of HKD 0.097 per share [1] - The total amounts for the subscription agreements are HKD 291 million for the first agreement, HKD 194 million for the second, and HKD 1.067 billion for the third [1] Group 2 - The net proceeds from the subscription agreements will be used for the potential new business development in health products, equipment, and technology trade, manufacturing, sales, and distribution in China [2] - The company aims to expand its health-related business opportunities into overseas markets while continuing to utilize its existing internal cash resources to maintain and develop its current pharmaceutical business [2]

Group 1 - The stock of Jingyou Pharmaceutical (00858) surged over 13%, reaching a price of 0.134 HKD with a trading volume of 2.323 million HKD [1] - The company announced three subscription agreements on August 14, 2025, with different investors, agreeing to issue a total of 136 million shares at a subscription price of 0.097 HKD per share [1] - The total amounts for the subscription agreements are 2.91 million HKD, 1.94 million HKD, and 10.67 million HKD respectively for the three agreements [1] Group 2 - The net proceeds from the subscription will be used for potential new business development in health products, equipment, and technology trade, manufacturing, sales, and distribution in China [2] - The company aims to expand its health-related business opportunities into overseas markets while continuing to utilize its existing cash resources to maintain and develop its current pharmaceutical business [2]

Group 1 - The stock of Jingyou Pharmaceutical (00858) surged over 13%, reaching a price of 0.134 HKD with a trading volume of 2.323 million HKD [1] - The company entered into subscription agreements with three different parties on August 14, 2025, for a total of 300 million HKD in new shares at a price of 0.097 HKD per share [1][2] - The total amount from the subscription agreements is 2.91 million HKD, 1.94 million HKD, and 10.67 million HKD respectively, with conditions that must be met for the agreements to be finalized [1][2] Group 2 - The net proceeds from the subscription agreements will be used for the development of new business opportunities in health products, equipment, and technology trade in China, as well as expanding into overseas markets [2] - The company will continue to utilize its existing cash resources to maintain and develop its current pharmaceutical business [2]

Group 1 - The company has entered into subscription agreements with three subscribers to issue a total of 160 million shares at a subscription price of HKD 0.097 per share, raising a total of HKD 2.91 million, HKD 1.94 million, and HKD 10.67 million respectively [2] - The net proceeds from the subscription will be used to support the group's potential new business development in the trade, manufacturing, sales, and distribution of health products, equipment, and technology in China, as well as to expand into overseas health-related business opportunities [2] - The company plans to continue using internal cash resources to maintain and develop its existing pharmaceutical business, believing that factors such as an aging population, increasing chronic diseases, heightened health awareness, and technological advancements will sustain the demand for health and patient care products and solutions in the healthcare industry [2]

Group 1 - The company has entered into three subscription agreements with different subscribers, agreeing to issue a total of 1.43 billion shares at a subscription price of HKD 0.097 per share, raising a total of HKD 1.55 billion [1][2] - The first agreement involves the issuance of 30 million shares for a total of HKD 2.91 million, the second agreement involves 20 million shares for HKD 1.94 million, and the third agreement involves 110 million shares for HKD 10.67 million [1] - The subscription matters are conditional and will only be finalized upon the fulfillment of specified conditions [1] Group 2 - The net proceeds from the subscription will be used to develop potential new business in health products, equipment, and technology trade, manufacturing, sales, and distribution in China, as well as to expand related business opportunities overseas [2] - The company believes that the demand for products and solutions that improve health and patient care will continue to grow due to factors such as an aging population, increasing prevalence of chronic diseases, heightened health awareness, and technological advancements [2] - The net proceeds will support the company in seizing new business opportunities more effectively [2]